Abbott Confirms Long-Term Commitment to HIV Care
- Details
- Category: Abbott
Abbott plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. The company is currently investigating a new powder formulation of Norvir as well as a co-formulation of three HIV medicines - lopinavir, ritonavir and 3TC (lamivudine).
Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers
- Details
- Category: Novartis
Novartis has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season. Early delivery of seasonal influenza vaccine will ensure healthcare professionals have the ability to provide the earliest possible protection against influenza.
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.
Roche provides update from FDA hearing on Avastin for metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin® (bevacizumab) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative metastatic breast cancer.
Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
- Details
- Category: Eli Lilly and Company
John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), urged that biopharmaceuticals be included in transatlantic trade and economic discussions.
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
- Details
- Category: Genzyme
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS).
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition
- Details
- Category: Boehringer Ingelheim
As part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world, Boehringer Ingelheim and Ashoka's Changemakers® announced the launch of the "Making More Health" Competition.
More Pharma News ...
- Phase III trial of Novartis drug Afinitor® met primary endpoint
- Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses
- Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
- Amgen and UCB Team Up with NASA
- London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency
- Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
- Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia